Recent developments include a merger announcement to form a public Zcash mining platform, endorsement of the MyoVista Insights™ platform by a hospital network, multiple buy recommendations by Ascendiant Capital, fiscal year 2025 financial results reporting, patent grants, scientific advisory board expansions, and ongoing commercial progress with AI-ECG innovations.

• Fortitude and HeartSciences announced a merger to form a public Zcash mining platform, with the stock price increasing following the announcement [N1].
• Cibolo Health designated HeartSciences’ MyoVista Insights™ as the endorsed ECG management platform for a network of 123 independent hospitals [N2].
• Ascendiant Capital maintained a buy recommendation for HeartSciences in December 2025 and October 2025 [N3][N4].
• HeartSciences reported fiscal year 2025 financial results and strategic advances in AI-enhanced ECG technology [N5].
• The company secured a foundational patent for AI-driven ECG technology enhancing heart function detection [N6].
• HeartSciences expanded its scientific advisory board with three new appointments to enhance AI-driven cardiac care [N7].
• Quarterly earnings results were reported in March 2025, including updates on AI-powered ECG innovations [N8].

HeartSciences has developed a scalable, cloud-native ECG management platform that integrates multiple AI-ECG algorithms, addressing significant clinical and operational gaps in ECG workflows. The platform’s vendor-agnostic design and Epic Toolbox designation facilitate integration into large healthcare IT ecosystems. The company’s AI-ECG marketplace model enables participation in a broad range of algorithmic innovations, potentially accelerating adoption. The MyoVista wavECG device, pending FDA clearance, complements the platform by enabling point-of-care ECG acquisition with embedded AI analysis. Recent endorsements by hospital networks and ongoing commercial discussions indicate progress toward revenue generation. The company’s patent portfolio and scientific advisory board expansion support continued innovation in AI-driven cardiac care.

HeartSciences faces regulatory risk related to the FDA 510(k) clearance process for its MyoVista wavECG device and associated AI algorithms, with no assurance of timing or approval. The company reported a net loss and liquidity constraints as of mid-2026, indicating financial challenges that may impact its ability to fund development and commercialization. Market adoption depends on successful integration into complex healthcare IT environments and acceptance by providers. Competition from established ECG and AI diagnostic companies may limit market penetration. The company’s reliance on third-party algorithms and licensing agreements introduces execution risks. Additionally, evolving clinical guidelines require ongoing algorithm validation and development, potentially delaying commercialization.

HeartSciences’ competitive strengths lie in its platform-centric strategy that focuses on workflow enablement and scalable integration of AI-ECG capabilities. The MyoVista Insights™ platform’s cloud-native, vendor- and device-agnostic architecture supports interoperability across diverse healthcare IT systems and ECG devices, reducing barriers to adoption. The AI-ECG marketplace model allows the company to benefit from multiple proprietary and third-party algorithms, mitigating dependency on any single algorithm’s success. The platform’s Epic Toolbox designation enhances its positioning within major healthcare IT ecosystems. Additionally, the company’s licensing agreements with Mount Sinai and its FDA Breakthrough Device Designation for an aortic stenosis algorithm contribute to its intellectual property and innovation moat. These factors collectively support differentiation in a growing AI-ECG market.

• Regulatory Approval Risk: The MyoVista wavECG device and associated AI algorithms are subject to FDA 510(k) clearance, with no assurance of approval timing or outcome, which could delay or prevent commercialization.
• Financial and Liquidity Risk: As of June 30, 2026, the company had a current ratio of 0.53 and a cash ratio of 0.34, indicating liquidity constraints that may affect its ability to fund operations and development.
• Market Adoption Risk: Successful integration of the platform and device into healthcare IT systems and clinical workflows is critical; failure to achieve adoption could limit revenue growth.
• Competitive Risk: The company operates in a competitive market with established ECG and AI diagnostic providers, which may challenge market penetration and pricing.
• Execution Risk: Dependence on third-party AI-ECG algorithms and licensing agreements introduces risks related to development, regulatory approval, and commercialization.
• Clinical and Algorithm Development Risk: Changes in clinical guidelines require ongoing validation and development of AI algorithms, potentially delaying product readiness and market entry.

• HeartSciences Inc. is a healthcare information technology company focused on advancing electrocardiography (ECG) through artificial intelligence integration.
• The company’s first commercial product is MyoVista Insights™, a cloud-native, vendor- and device-agnostic ECG management platform designed to modernize ECG workflows and enable scalable AI-ECG deployment across healthcare systems.
• MyoVista Insights™ is classified as a Medical Device Data System (MDDS) and is exempt from FDA 510(k) requirements.
• The platform supports centralized ECG storage, advanced waveform visualization, workflow optimization, interoperability with electronic medical records and ECG devices, and integration of multiple AI-ECG algorithms within clinical workflows.
• MyoVista Insights™ includes an AI-ECG marketplace hosting algorithms from HeartSciences and third parties, with ongoing discussions for commercialization arrangements.
• In March 2026, a significant version upgrade was released including mobile device access, enhanced reporting, and expanded interoperability for large health systems.
• MyoVista Insights™ received Epic Toolbox designation from Epic Systems Corporation, supporting positioning within enterprise healthcare IT ecosystems.
• The company has developed the MyoVista wavECG™ device, a 12-lead ECG system designed to complement the platform by enabling point-of-care ECG acquisition and analysis with embedded AI-ECG algorithms.
• The MyoVista wavECG device was submitted to the FDA for 510(k) premarket clearance in December 2025; the submission remains under review with no assurance of clearance timing or outcome.
• The company separates FDA submissions for the device and an impaired cardiac relaxation (e’) AI algorithm under development, requiring additional validation to align with updated clinical standards.
• HeartSciences plans to generate revenue from installation fees, SaaS usage fees, and fees associated with AI-ECG algorithms on its marketplace.
• The company highlights a significant unmet need for early identification of heart disease and structural gaps in ECG data management and utilization.
• MyoVista Insights™ aims to address legacy system limitations by providing a cloud-native, scalable ECG management platform suitable for primary care through large health systems, including underpenetrated international markets.
• The platform’s vendor- and device-agnostic architecture supports operation across a wide range of ECG devices and healthcare IT systems.
• The company holds multiple license agreements with Mount Sinai for AI-ECG algorithms, including one with FDA Breakthrough Device Designation for aortic stenosis.
• HeartSciences has expanded its scientific advisory board to enhance AI-driven cardiac care.
• The company reported a net loss of $9.14 million for the fiscal year ending April 30, 2026, and a basic EPS of -$3.48 for the same period.
• As of June 30, 2026, the company had cash and equivalents of approximately $1.66 million, current assets of $2.58 million, current liabilities of $4.86 million, a current ratio of 0.53, and a cash ratio of 0.34, indicating liquidity constraints.
• The company’s business model and product strategy are supported by multiple recent news reports including merger announcements, endorsements by hospital networks, patent grants, and financial results disclosures.